Results 91 to 100 of about 64,353 (271)

Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery

MedComm – Oncology, Volume 5, Issue 1, March 2026.
This review summarizes the molecular mechanisms that regulate tumor dormancy and its role in cancer recurrence, with emphasis on immune evasion, extracellular matrix remodeling, metabolic regulation and angiogenic switching. It further discusses emerging peptide–based therapeutic strategies aimed at detecting, modulating, and eliminating dormant tumor ...
Abdur Raheem Aleem, Atif Ali, Wajid Ali, Yuying Cheng, Zhibin Yan, Chaoyi Xia, Chenguang Liu, Caiyun Fu, Yiren Hu, Xi Wang   +9 more
wiley   +1 more source

Sarcomatous mesothelioma in the left ventricle: A rare entity [PDF]

, 2001
Jianyang Ma, Xiuhui Zhang, Hongsheng Yuan, Dong Sheng Li, Huaibin Zhang, Shi Ying-kang   +5 more
openalex   +1 more source

Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang, Xue Sun, Xinhao Han, Xingda Zhang, Wenzheng Wang, Hongbin Wang, He Ren, Lina Gu   +7 more
wiley   +1 more source

Global, Population and Genetic Evidence on the Relationships Between Immune‐Mediated Inflammatory Disease and Cancer Risk

Cancer Innovation, Volume 5, Issue 1, February 2026.
Using a triangulation framework that synthesizes findings across global, population and genetic perspectives, this work comprehensively establishes associations between six immune‐mediated inflammatory diseases (IMIDs) and 33 cancers, identifying 170 statistically significant IMID‐cancer pairs, validating 20 in the UKBB cohort and uncovering a causal ...
Xuesi Dong, Jiaxin Xie, Zilin Luo, Hao Hong, Chenran Wang, Yadi Zheng, Xiaoyue Shi, Zeming Guo, Xiaolu Chen, Yongjie Xu, Wei Cao, Fei Wang, Dong Hang, Sipeng Shen, Fengwei Tan, Ni Li   +15 more
wiley   +1 more source

T‐cell receptor–like chimeric antigen receptor T cells targeting mesothelin: A first‐in‐human dose‐escalation trial for platinum‐resistant advanced ovarian cancer

Cancer, Volume 132, Issue 3, 1 February 2026.
Abstract Background Ovarian cancer remains a formidable therapeutic challenge due to late diagnosis, high recurrence rates, and limited treatment options. Mesothelin (MSLN) is highly expressed in ovarian cancer, making it a promising target for immunotherapy.
Yiyang Shan, Bo Ding, Feng Ji, Hao Lin, Weiwei Shi, Enxiu Wang, Chen Wang, Yang Shen   +7 more
wiley   +1 more source

Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic‐cell clearance to therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
This review systematically deconstructs the pathological efferocytic—metabolic axis in tumours, framing it as a three‐stage, self‐reinforcing cycle: from metabolite‐driven macrophage recruitment, through hijacked surface recognition, to post‐phagocytic metabolic reprogramming that locks in immunosuppression.
Qianlu Yang, Jie Yan, Qianxi Yang
wiley   +1 more source

Lymphocyte Predominance in Blood, Pleural Fluid, and Tumour Stroma; A Prognostic Marker in Pleural Mesothelioma [PDF]

, 2021
Duneesha de Fonseka, David Arnold, Anna J. Morley, Mary Brett, Nidhi Bhatt, Anthony Edey, Richard Daly, Anna Bibby, Nick Maskell   +8 more
openalex   +1 more source

Body height and the excess cancer risk in men

International Journal of Cancer, Volume 158, Issue 3, Page 597-607, 1 February 2026.
What's new? In cancers that affect both sexes, men usually have a higher risk than women. While this is often attributed to behavioral factors, such as exposure to environmental carcinogens, there may be an intrinsic biological mechanism involved. Tall stature has been associated with increased cancer risk.
Cecilia Radkiewicz, Gustaf Edgren, Arvid Sjölander, Emelie Benyi, Mats Lambe, Paul W. Dickman, Lars Sävendahl   +6 more
wiley   +1 more source

Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation

MedComm, Volume 7, Issue 2, February 2026.
Tumor‐associated macrophages are the most abundant immune cells in the tumor microenvironment, driving malignant progression and treatment resistance. This review summarizes the protumor mechanisms of TAMs (including phagocytosis modulation, metabolic reprogramming, exosomal communication, and immune interactions), evaluates three major strategies ...
Wurihan Bao, Xiaojie Qu, Yiqi Wang, Dan Huang, Huiling Zhang, Mingyuan Dong, Han Sun, Zhaogang Yang, Xuefeng Li   +8 more
wiley   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 382-408, 15 January 2026.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source